This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
| colspan="2" style="text-align:center;font-size:7pt" | [[Image:5-meo-mipt.gif|noframe|297px]]<br />The skeletal formula of 5-MeO-MIPT
'''5-Methoxy-N-methyl-N-isopropyltryptamine''' (also known as '''5-MeO-MiPT''' and '''moxy''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. 5-MeO-MiPT is chemically related to tryptamines like [[5-MeO-DMT]] and [[5-MeO-DiPT]]. It produces its psychoactive effects through activity at [[serotonin]] [[receptors]] in the brain.
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.<ref name="Repke1985">{{cite journal|last1=Repke|first1=D. B.|last2=Grotjahn|first2=D. B.|last3=Shulgin|first3=A. T.|author-link3=Alexander Shulgin|title=Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents|journal=Journal of Medicinal Chemistry|year=1985|volume=28|issue=7|pages=892–896|doi=10.1021/jm00145a007|pmid=4009612|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> Its effects in humans was documented in Shulgin's book [[TiHKAL]] ("Tryptamines I Have Known and Loved").
Anecdotal reports describe 5-MeO-MiPT's effects as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a [[research chemical]]. It is highly advised to use harm reduction practices when using this substance.
|-
| style="font-size:9pt" | Common || style="font-size:9pt" | 8-14<sub>mg</sub>
==Chemistry==
|-
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R<sub>5</sub> of its indole heterocycle with a methoxy (MeO) functional group CH<sub>3</sub>O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine R<sub>N</sub> of its tryptamine backbone (MiPT).
5-MeO-MiPT is the N-substituted isopropyl homologue of [[5-MeO-DMT]].<ref name="TiHKAL">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|year=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|chapter-url=https://erowid.org/library/books_online/tihkal/tihkal40.shtml|chapter=#40. 5-MeO-MiPT}}</ref>
| style="font-size:9pt" | Heavy || style="font-size:9pt" | 20-25+<sub>mg</sub>
5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> but other studies have not found significant action at the monoamine transporters[https://www.sciencedirect.com/science/article/abs/pii/S0924977X16300426]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
| style="font-size:9pt" | Onset|| style="font-size:9pt" | 20 - 60 mins
5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels [[stimulant|stimulating]] and [[entactogens|entactogenic]] whilst the second half feels more similar to a traditional [[tryptamine]] [[psychedelic]] like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.
*'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
|-
*'''[[Effect::Nausea]]''' - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to [[5-MeO-DiPT]], this substance has a much lower tendency to trigger unpleasant physical reactions.
| style="font-size:9pt" | Common || style="font-size:9pt" | 10-15<sub>mg</sub>
*'''[[Effect::Stomach bloating]]''' - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
'''5-MeO-MIPT''', or '''5-methoxy-N-methyl-N-isopropyltryptamine''' also known as '''Moxy''' is a [[psychedelics|psychedelic]] and [[enactogen|entactogenic]] drug in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of the psychedelic 5-MeO-DMT. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT.
====Distortions====
*'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Melting|Melting]], [[Visual drifting#Breathing|Breathing]], [[Visual drifting#Warping|Warping]] and [[Visual drifting#Flowing|Flowing]])'' - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
*'''[[Effect::Tracers]]'''
*'''[[Effect::After images]]'''
*'''[[Effect::Symmetrical texture repetition]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Scenery slicing]]'''
5-MeO-MIPT has no history of human usage prior to the 1985 publication of its synthesis and pharmacology in the Journal of Medicinal Chemistry by Repke, Grotjahn & Shulgin. <ref>http://pubs.acs.org/doi/abs/10.1021/jm00145a007</ref> In modern times it is used as a recreational drug and an entheogen, rarely sold on the streets and almost exclusively obtained as a grey area research chemical through the use of online vendors.
====Geometry====
The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of [[Psilocin]], [[4-AcO-DMT]] or [[ayahuasca]] than that of [[LSD]] or [[2C-B]]. It can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].
=Pharmacology=
====Hallucinatory states====
The mechanism that produces the hallucinogenic and entactogenic effects of 5-MeO-MiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as inhibition of MAO may be involved also.
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
=Subjective effects=
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their [[Visual_effects:_Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
==Differences in methods of consumption==
}}
This substance can be taken via oral ingestion or it can be smoked. When ingested orally the experience puts more of an emphasis on visual effects but can be broken up into two stages, the first half of the trip feels stimulating and entactogenic and the second half feelsmore similar to a traditional typtamine psychedelic.
|{{effects/cognitive|
If smoked however these stages of experience are not present and the experience places more of an emphasis on physically and cognitively stimulating effects accompanied by subtle and mild changes in visual perception.
At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical [[psychedelic]] cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with [[depersonalization]] and no accompanying insight.
The physical effects of LSD can be broken down into five components all of which progressively intensify proportional to dosage.
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as [[MDMA]] and [[2C-B]] but still prove strong enough to provide long-lasting therapeutic effects.
*'''[[Effect::Depersonalization]]''' - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Increased libido]]''' - increased libido and significantly enhanced orgasms are reported
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Personal bias suppression]]'''
*'''[[Effect::Thought acceleration]]'''
*'''[[Effect::Thought connectivity]]'''
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Wakefulness]]'''
*'''[[Physical effects: Spontaneous tactile sensations|Spontaneous tactile sensations]]''' - the body high of 5-MeO-MIPT can be described as a pleasurable, warm, soft and all encompassing glow. There is also a cold, sharp tingling sensation that is manifested spontaneously at different unpredictable points throughout the trip but for others it can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
}}
*'''[[Physical effects: Stimulation|Stimulation]]''' and '''[[Physical effects: Sedation|Sedation]]''' - in terms of its effects on the physical energy levels of the tripper, 5-MeO-MIPT can be both sedating and stimulating. The physical energy levels seem to manifest themselves in waves in an unpredictable pattern. This seems to be partially setting dependant and during physically strenuous situations such as running or dancing it can become stimulating and energetic. In contrast however, in calm environments such as darkened rooms with comfortable seating it can become relaxing, peaceful and even moderately sedating.
{{effects/auditory|
*'''[[Physical effects: Nausea|Nausea]]''' - as the tripper begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this over or the trip begins to fully set in. In comparison to other psychedelics such as [[psilocin]], [[LSD]], and [[2C-E]], this could actually be very considered very mild in its intensity. In comparison to [[5-MeO-DIPT]], 5-MeO-MIPT has a much lower tendency to trigger unpleasant physical reactions and has been described as much less physically stimulating.
The head space of 5-MeO-MIPT is described by many as one which is both insightful and moderately relaxing, but at some points quite stimulating. This manifests itself as two different styles of head space that depend both on the setting and the way in which this drug manifests its self in varying waves.
}}
}}
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
For example, when taken with others these effects seems to have very strong [[Entactogens|entactogenic]] effects, which can become quite stimulating. These feelings of [[Cognitive effects: Increased empathy, love and sociability|increased empathy, love and sociability]] are a little weaker and less sharp than those found on substances such as [[MDMA]] or [[2C-B]] but still are prove stronger and more consistent than most other psychedelics of any class, proving to be capable of providing long lasting therapeutic effects.
When this substance is taken alone however, the entacogenic effects are replaced with typical psychedelic introspection. These two alternate sets of present cognitive effects seem to be a prominent stimulation coupled with a relaxing clarity, shifting into each other based on the users current current mind state and external environmental factors.
==Reagent results==
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from [https://www.protestkit.eu/results/ ProTestKit].
{| class="wikitable"
!5-MeO-MiPT
!Marquis
!Mecke
!Mandelin
!Liebermann
!Ehrlich
!Hofmann
!Simon’s
|-
|Freebase
|Orange - brown
|Orange red
|Deep greenish brown
|Unknown
|Purple
|No reaction
|No reaction
|-
|HCl
|Orange - brown
|Red - brown
|Greenish brown
|Brown
|Violet - purple
|Green
|Unknown
|}
Along side of these two alternate sets of effects, this substance produces a large number of general psychedelic cognitive effects. The most prominent of these include:
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
Almost nothing is known about the long-term effects of 5-MeO-MiPT. Alongside of this, the exact toxic dosage is unknown. This is because 5-MeO-MiPT is a [[research chemical]] with very little history of human use.
A preliminary study on mice has shown that a normal dose of 5-MeO-MiPT (0.27 mg/kg) was unable to produce any measurable toxic effects.<ref name=":0">Altuncı YA, Aydoğdu M, Açıkgöz E, Güven Ü, Düzağaç F, Atasoy A, Dağlıoğlu N, Annette Akgür S. [https://pubmed.ncbi.nlm.nih.gov/32936075/ New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.] Balkan Med J. 2021 Jan;38(1):34-42. [[wikipedia:Digital_object_identifier|doi]]:[https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.68 10.4274/balkanmedj.galenos.2020.2019.11.68] [[wikipedia:PubMed_Identifier|PMID]]: [https://pubmed.ncbi.nlm.nih.gov/32936075/ 32936075]; [https://en.wikipedia.org/wiki/PubMed_Central#PMCID PMCID]: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8909217/ PMC8909217].
*'''[[Cognitive effects: Acceleration of thought|Acceleration of thought]]'''
*'''[[Cognitive effects: Connectivity of thought|Connectivity of thought]]'''
*'''[[Cognitive effects: Enhancement of current mind state|Enhancement of current mind state]]'''
*'''[[Cognitive effects: Removal of cultural filter|Removal of cultural filter]]'''
*'''[[Cognitive effects: Feelings of fascination, importance and awe|Feelings of fascination, importance and awe]]'''
<br /></ref> However, doses of 5-MeO-MiPT way above the normal dosage range (2.7 mg/kg) have been shown to produce cell toxicity by triggering programmed cell death in the brain, liver and kidneys. The extent of the damage, if it occurs in other bodily tissues as well and how it is caused is not known yet.
===[[Visual effects - Psychedelics#Visual Distortions and Alterations|Distortions]]===
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
As for visual distortions and alterations, these generally include:
*'''[[Visual effects: Drifting|Drifting]]''' ''([[Visual effects: Drifting#Melting|Melting]], [[Visual effects: Drifting#Breathing|Breathing]], [[Visual effects: Drifting#Warping|Warping]] and [[Visual effects: Drifting#Flowing|Flowing]])'' - in comparison to other psychedelics this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of [[Psilocin]], [[4-AcO-DMT]] or [[Ayahuasca]] than that of [[LSD]] or [[2C-B]]. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, equal in blurred and sharp edges and equal in rounded and angular corners. At higher dosages they are significantly more likely to result in states of [[Visual effects - Psychedelics#7B_-_Exposure_to_inner_mechanics_of_human_consciousness|level 7B]] visual geometry over [[Visual effects - Psychedelics#7A_-_Exposure_to_entirety_of_neurological_structure|level 7A]].
===Tolerance and addiction potential===
5-MeO-MiPT is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating.
In terms of their manifestation they are progressive in nature and continuously self complexify in settings with little or no visual input and disturbances. For example, darkness will cause the geometry to progressively intensify but this can immediately be reset back down to base level by simply turning on a bright light or actively performing a physical task which requires any level of concentration.
Tolerance to the effects of 5-MeO-MiPT is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
5-MeO-MIPT is capable of producing level 1 - 3 hallucinatory states and has been reported to produce a full range of high level hallucinatory states. These effects include:
*'''[[Visual effects: Internal hallucinations (psychedelic)|Internal hallucinations]]''' - this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively religious, spiritual, mystical or transcendental nature in their overall theme.
There are no known deaths from 5-MeO-MiPT but, as a [[monoamine]] [[reuptake inhibitor]] (MRI)<ref name="pmid17223101" />, injury could occur when excessive doses are taken or when it is taken with drugs such as [[MAOIs]], [[RIMA]]s, [[stimulant]]s and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[neurotransmitters]] such as [[serotonin]] and [[dopamine]].<ref>{{cite journal|title=Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity|url=https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext|doi=10.1093/bja/aei210|last=Gillman|first=P. K.|journal=British Journal of Anaesthesia|volume=95|issue=4|year=2005|pages=434–441|issn=0007-0912|eissn=1471-6771|oclc=01537271}}</ref>
The auditory effects of 5-MeO-MIPT are common in their occurrence and exhibit a full range of effects which commonly includes,
The toxicity of 5-MeO-MiPT is not known but as with all research chemicals doses should be carefully weighed on an accurate milligram scale and users should take extreme caution to work their way up from thresh hold dosages. There are many reports of vasoconstriction and uncomfortable increases in heart rate and this should be taken into account.
5-MeO-MIPT and MAOIs are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5MeO-MIPT unpredictably. Taking this chemical while under the influence of Ayahuasca, harmala alkaloids, AMT and prescription MAOIs such as certain antidepressants is strongly discouraged.
*'''Austria''': 5-MeO-MiPT is illegal to possess, produce and sell under the NPSG (''Neue Psychoaktive Substanzen Gesetz'').<ref>[https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007605 Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Gesetz] ''(in german). Bundeskriminalamt Österreich. Retrieved April 13, 2023.''</ref> However, offenders with no intent to distribute will likely not have to face prosecution.
*'''Brazil''': 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref>
*'''China''': 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.<ref>{{cite web|title=Erowid China Psychoactive Law Update: September 2015|url=https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf|access-date=September 29, 2020|publisher=Erowid}}</ref>
*'''Finland''': 5-MeO-MiPT was banned in Finland in December 2014.<ref>{{cite web|title=1130/2014: Valtioneuvoston asetus: kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista|publication-date=December 19, 2014|url=https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf|work=Suomen Säädöskokoelma|language=fi}}</ref>
*'''Germany''': 5-MeO-MiPT is controlled under the NpSG<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> (''New Psychoactive Substances Act'') as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|language=de|issn=0341-1095}}</ref> Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__3.html|title=§ 3 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.<ref>{{cite web|url=http://dip21.bundestag.de/dip21/btd/18/085/1808579.pdf|title=Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|page=20|date=May 30, 2016|id=Drucksache 18/8579|publisher=Deutscher Bundestag|language=de}}</ref>
*'''Japan''': 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.{{citation needed}}
*'''Latvia''': 5-MeO-MiPT is a Schedule I drug in Latvia.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''Luxembourg''': 5-MeO-MiPT is not cited in the list of prohibited substances<ref>{{Citation | title=Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | url=https://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo}}</ref>. Therefore, it is still a legal substance.
*'''New Zealand''': 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.<ref>{{cite web|url=http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576|title=Schedule 1: Class A controlled drugs|access-date=September 19, 2020|work=Misuse of Drugs Act 1975|publisher=Parliamentary Counsel Office (PCO)}}</ref>
*'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}}
*'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>
*'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.<ref>https://www.law.cornell.edu/uscode/text/21/813</ref>
**'''Florida''': 5-MeO-MiPT is a Schedule I drug in Florida.<ref>{{cite web|title=The 2015 Florida Statutes - Chapter 893|url=http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html|publisher=The Florida Legislature|access-date=July 18, 2020}}</ref>
**'''Louisiana''': 5-MeO-MiPT is a Schedule I drug (as of June 2013).<ref>{{cite web|title=5-MeO-MIPT: Legal Status|publisher=Erowid|url=https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml|date=July 7, 2005|access-date=September 29, 2020}}</ref>
**'''Minnesota''': Minnesota banned a series of drugs including 5-MeO-MiPT.<ref>{{cite web|title=2019 Minnesota Statutes|publisher=Office of the Revisor of Statutes|year=2019|access-date=September 29, 2020|url=https://www.revisor.mn.gov/statutes/?id=152.02}}</ref>
==Tolerance and Addiction Potential==
==See also==
5-MeO-MIPT is not physically addictive, and many users experience a frequency self-regulating quality to the drug. Tolerance seems to be very moderate and does not build up without repeated use over a short period of time.
=Legal Issues=
*[[Responsible use]]
*'''USA:''' 5-MeO-MIPT is technically not scheduled in the United States, but could be considered an analogue of 5-MeO-DMT and therefore a Schedule I drug.
*'''UK:''' 5-MeO-MiPT is a Class A drug in the United Kingdom, as are most ethers of ring-hydroxy tryptamines.
*'''Romania:''' 5-MeO-MIPT and other derivatives are illegal in Romania, as of January 2011.
*'''Japan:''' 5-MeO-MIPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT and moxy) is a lesser-known psychedelic substance of the tryptamine class. 5-MeO-MiPT is chemically related to tryptamines like 5-MeO-DMT and 5-MeO-DiPT. It produces its psychoactive effects through activity at serotoninreceptors in the brain.
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.[1] Its effects in humans was documented in Shulgin's book TiHKAL ("Tryptamines I Have Known and Loved").
Anecdotal reports describe 5-MeO-MiPT's effects as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices when using this substance.
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT).
5-MeO-MiPT is the N-substituted isopropyl homologue of 5-MeO-DMT.[2]
5-MeO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist[3][1] and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor[4] but other studies have not found significant action at the monoamine transporters[1]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
Subjective effects
5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptaminepsychedelic like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of LSD.
Spontaneous bodily sensations - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
Nausea - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to 5-MeO-DiPT, this substance has a much lower tendency to trigger unpleasant physical reactions.
Stomach bloating - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
Drifting(Melting, Breathing, Warping and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.
Hallucinatory states
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Cognitive effects
At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.
Empathy, affection, and sociability enhancement - This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
Depersonalization - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from ProTestKit.
Almost nothing is known about the long-term effects of 5-MeO-MiPT. Alongside of this, the exact toxic dosage is unknown. This is because 5-MeO-MiPT is a research chemical with very little history of human use.
A preliminary study on mice has shown that a normal dose of 5-MeO-MiPT (0.27 mg/kg) was unable to produce any measurable toxic effects.[5] However, doses of 5-MeO-MiPT way above the normal dosage range (2.7 mg/kg) have been shown to produce cell toxicity by triggering programmed cell death in the brain, liver and kidneys. The extent of the damage, if it occurs in other bodily tissues as well and how it is caused is not known yet.
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
5-MeO-MiPT is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-MiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
2C-T-X - Both classes of compounds can be unpredictable alone.
2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
DXM - Little information exists about this combination.
Austria: 5-MeO-MiPT is illegal to possess, produce and sell under the NPSG (Neue Psychoaktive Substanzen Gesetz).[7] However, offenders with no intent to distribute will likely not have to face prosecution.
Brazil: 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.[8]
China: 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.[9]
Finland: 5-MeO-MiPT was banned in Finland in December 2014.[10]
Germany: 5-MeO-MiPT is controlled under the NpSG[11] (New Psychoactive Substances Act) as of July 18, 2019.[12] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[13][14] The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.[15]
Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.[citation needed]
Latvia: 5-MeO-MiPT is a Schedule I drug in Latvia.[16]
Luxembourg: 5-MeO-MiPT is not cited in the list of prohibited substances[17]. Therefore, it is still a legal substance.
New Zealand: 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.[18]
Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.[citation needed]
Switzerland: 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.[19]
Turkey: 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.[20]
United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.[21]
United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[22]
Florida: 5-MeO-MiPT is a Schedule I drug in Florida.[23]
Louisiana: 5-MeO-MiPT is a Schedule I drug (as of June 2013).[24]
Minnesota: Minnesota banned a series of drugs including 5-MeO-MiPT.[25]
